Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease
Seong Mi Moon, In Young Yoo, Hee Jae Huh, Nam Yong Lee, Byung Woo Jhun
Antimicrobial Agents and Chemotherapy · 2019-10
Abstract
We evaluated the efficacy of intermittent azithromycin and ethambutol therapy for noncavitary Mycobacterium avium complex pulmonary disease (MAC-PD). Twenty-nine (76%) of 38 patients achieved sputum culture conversion after 12 months of treatment, and sputum smear positivity was an independent factor for failure to achieve culture conversion (adjusted odds ratio, 26.7; 95% confidence interval, 2.1 to 339.9; P = 0.011).
MeSH terms
- Ethambutol
- Azithromycin
- Medicine
- Culture conversion
- Internal medicine
- Sputum
- Sputum culture
- Regimen
- Odds ratio
- Antibacterial agent
- Mycobacterium avium-intracellulare infection
- Rifampicin
- Mycobacterium avium complex
- Antibiotics
- Tuberculosis
- Mycobacterium
- Gastroenterology